<DOC>
	<DOCNO>NCT01472627</DOCNO>
	<brief_summary>The purpose study well understand effect Bortezomib , drug use multiple myeloma therapy , immune system .</brief_summary>
	<brief_title>Effects Bortezomib-Based Therapy Cellular Immunity Response DC/Myeloma Fusion Vaccines Vitro</brief_title>
	<detailed_description>Subjects study receive treatment multiple myeloma accord standard care regimen contain Bortezomib . If bone marrow sample clinically indicate guide treatment , additional 1 tablespoon specimen obtain laboratory study . Approximately 3 tablespoon blood take research purpose therapy Bortezomib start . When subject return follow-up cycle 1 , 2 , 3 additional 3 tablespoon blood take research purpose . Optional sample blood may take follow-up visit cycle 4 , 5 6 1 , 3 6 month complete therapy . This study also include medical record review .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Newly diagnose multiple myeloma Therapy bortezomib alone bortezomib/dexamethasone initiated standard care therapy myeloma treat physician Hypersensitivity bortezomib , boron mannitol Treatment investigational drug within 28 day enrollment Diagnosed treat another malignancy within 6 month enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy Use myeloma direct therapy ( except dexamethasone ) combination bortezomib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MM</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Velcade</keyword>
</DOC>